| European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013 M Baccarani, MW Deininger, G Rosti, A Hochhaus, S Soverini, ... Blood, The Journal of the American Society of Hematology 122 (6), 872-884, 2013 | 2678 | 2013 |
| Standardization and quality control studies of ‘real-time’quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection … J Gabert, E Beillard, VHJ Van der Velden, W Bi, D Grimwade, ... Leukemia 17 (12), 2318-2357, 2003 | 1961 | 2003 |
| Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet M Baccarani, J Cortes, F Pane, D Niederwieser, G Saglio, J Apperley, ... Journal of clinical oncology 27 (35), 6041-6051, 2009 | 1902 | 2009 |
| European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia A Hochhaus, M Baccarani, RT Silver, C Schiffer, JF Apperley, F Cervantes, ... Leukemia 34 (4), 966-984, 2020 | 1467 | 2020 |
| Ruxolitinib versus standard therapy for the treatment of polycythemia vera AM Vannucchi, JJ Kiladjian, M Griesshammer, T Masszi, S Durrant, ... New England Journal of Medicine 372 (5), 426-435, 2015 | 1055 | 2015 |
| BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European … S Soverini, A Hochhaus, FE Nicolini, F Gruber, T Lange, G Saglio, F Pane, ... Blood, The Journal of the American Society of Hematology 118 (5), 1208-1215, 2011 | 758 | 2011 |
| Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia S Soverini, S Colarossi, A Gnani, G Rosti, F Castagnetti, A Poerio, ... Clinical Cancer Research 12 (24), 7374-7379, 2006 | 659 | 2006 |
| Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction)[see comments] F Pane, F Frigeri, M Sindona, L Luciano, F Ferrara, R Cimino, G Meloni, ... | 603 | 1996 |
| Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study F Passamonti, C Cattaneo, L Arcaini, R Bruna, M Cavo, F Merli, ... The Lancet Haematology 7 (10), e737-e745, 2020 | 592 | 2020 |
| Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib C Gambacorti-Passerini, L Antolini, FX Mahon, F Guilhot, M Deininger, ... Journal of the National Cancer Institute 103 (7), 553-561, 2011 | 550 | 2011 |
| ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression … S Soverini, G Martinelli, G Rosti, S Bassi, M Amabile, A Poerio, B Giannini, ... Journal of clinical oncology 23 (18), 4100-4109, 2005 | 487 | 2005 |
| Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient … S Branford, L Fletcher, NCP Cross, MC Müller, A Hochhaus, DW Kim, ... Blood, The Journal of the American Society of Hematology 112 (8), 3330-3338, 2008 | 481 | 2008 |
| Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia NCP Cross, HE White, D Colomer, H Ehrencrona, L Foroni, E Gottardi, ... Leukemia 29 (5), 999-1003, 2015 | 386 | 2015 |
| IKZF1 (Ikaros) Deletions in BCR-ABL1–Positive Acute Lymphoblastic Leukemia Are Associated With Short Disease-Free Survival and High Rate of Cumulative … G Martinelli, I Iacobucci, CT Storlazzi, M Vignetti, F Paoloni, D Cilloni, ... Journal of Clinical Oncology 27 (31), 5202-5207, 2009 | 377 | 2009 |
| Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RARα fusion gene in patients with acute promyelocytic leukemia … D Diverio, V Rossi, G Avvisati, S DeSantis, A Pistilli, F Pane, G Saglio, ... Blood, The Journal of the American Society of Hematology 92 (3), 784-789, 1998 | 367 | 1998 |
| Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in … JE Cortes, M Baccarani, F Guilhot, BJ Druker, S Branford, DW Kim, ... Journal of Clinical Oncology 28 (3), 424-430, 2010 | 359 | 2010 |
| Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia G Rosti, F Palandri, F Castagnetti, M Breccia, L Levato, G Gugliotta, ... Blood, The Journal of the American Society of Hematology 114 (24), 4933-4938, 2009 | 293 | 2009 |
| Wilson disease protein ATP7B utilizes lysosomal exocytosis to maintain copper homeostasis EV Polishchuk, M Concilli, S Iacobacci, G Chesi, N Pastore, P Piccolo, ... Developmental cell 29 (6), 686-700, 2014 | 283 | 2014 |
| Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1–positive acute … I Iacobucci, CT Storlazzi, D Cilloni, A Lonetti, E Ottaviani, S Soverini, ... Blood, The Journal of the American Society of Hematology 114 (10), 2159-2167, 2009 | 273 | 2009 |
| Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study M Baccarani, G Rosti, F Castagnetti, I Haznedaroglu, K Porkka, ... Blood, The Journal of the American Society of Hematology 113 (19), 4497-4504, 2009 | 256 | 2009 |